SGX Gets Boehringer Ingelheim Deal
Structural Genomix of San Diego, Calif., and Boehringer Ingelheim Pharmaceuticals said last week they started a two-year collaboration. Under the agreement, SGX will solve the three dimensional structures of protein targets provided by Boehringer. Subsequently, SGX will generate co-crystals with potential drug lead compounds.
Boehringer hopes that SGX's high-throughput protein structure determination platform will help it optimize lead compounds and improve drug candidates.